(Q28296162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

HIV entry inhibitors: mechanisms of action and resistance pathways (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Eva Poveda

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Vicente Soriano

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

Verónica Briz

0 references

language of work or name

English

0 references

publication date

7 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

619-627

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

The CD4 antigen: physiological ligand and HIV receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Energetics of the HIV gp120-CD4 binding reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

The antigenic structure of the HIV gp120 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Emerging drug targets for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A new classification for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

HIV-1 inhibition by a peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

US FDA approves new class of HIV therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Novel therapies based on mechanisms of HIV-1 cell entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL027

21 January 2018

Identifiers

DOI

10.1093/JAC/DKL027

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16464888%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017